Pharmacokinetics-Driven Optimization of 4(3 H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension.
Wang Z, Jiang X, Zhang X, Tian G, Yang R, Wu J, Zou X, Liu Z, Yang X, Wu C, Shi J, Li J, Suo J, Wang Y, Zhang R, Xu Z, Gong X, He Y, Zhu W, Aisa HA, Jiang H, Xu Y, Shen J.
Wang Z, et al. Among authors: shen j.
J Med Chem. 2019 May 23;62(10):4979-4990. doi: 10.1021/acs.jmedchem.9b00123. Epub 2019 May 8.
J Med Chem. 2019.
PMID: 31021628